ArticleJournal of the American Geriatrics Society2020
Physician Perspectives on Deprescribing Cardiovascular Medications for Older Adults.
Article in Journal of the American Geriatrics Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Deprescribing statins for adults 65 years of age and older: Evidence-based clinical practice guideline.Canadian family physician Medecin de famille canadien · 2026Guideline
- Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review.BMJ open · 2022Pooled it
- Pharmacist-led deprescribing of cardiovascular and diabetes medication within a clinical medication review: the LeMON study (Less Medicines in Older Patients in the Netherlands), a cluster randomized controlled trial.International journal of clinical pharmacy · 2025Trial
- Ethical Aspects of Physician Decision-Making for Deprescribing Among Older Adults With Dementia.JAMA network open · 2023Trial
- Instruments for assessing healthcare professionals' knowledge, attitudes and practices regarding deprescribing: a scoping review.International journal of clinical pharmacy · 2026Review
- Article
- Long-term beta blocker prescribing after myocardial infarction in European primary care (PRACTITIONER).BMC primary care · 2026Article
- Approaches to deprescribing cardiovascular medications in patients receiving palliative care: a scoping review.Clinical hypertension · 2026Review
- A randomized controlled trial to evaluate innovative decision support in the context of fall prevention.NPJ digital medicine · 2025Article
- Article
- Deprescribing strategies in older patients with heart failure.Internal and emergency medicine · 2025Review
- A National Physician Survey Examining Switching From Sulfonylureas or Insulin to Newer Diabetes Medications.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Engagement of outpatient providers in a deprescribing trial for hospitalized older patients transitioning to post-acute care facilities.Health literacy and communication open · 2025Article
- Review
- A National Survey of Physicians' Views on the Importance and Implementation of Deintensifying Diabetes Medications.Journal of general internal medicine · 2024Article
- Evaluation of deprescription by general practitioners in elderly people with different levels of dependence: cross-sectional study.BMC primary care · 2024Article
- Unlocking Deprescribing Potential in Nursing Homes: Insights from a Focus Group Study with Healthcare Professionals.Drugs & aging · 2024Article
- Factors influencing healthcare providers' behaviours in deprescribing: a cross-sectional study.Journal of pharmaceutical policy and practice · 2024Article
- Deprescribing, shared decision-making, and older people: perspectives in primary care.Journal of pharmaceutical policy and practice · 2023Review
- Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review.European geriatric medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 2 countries.
Funding
Abstract
BACKGROUND/
objectivesGuideline-based management of cardiovascular disease often involves prescribing multiple medications, which contributes to polypharmacy and risk for adverse drug events in older adults. Deprescribing is a potential strategy to mitigate these risks. We sought to characterize and compare clinician perspectives regarding deprescribing cardiovascular medications across three specialties.
designNational cross-sectional survey.
settingAmbulatory.
participantsRandom sample of geriatricians, general internists, and cardiologists from the American College of Physicians. MEASUREMENTS: Electronic survey assessing clinical practice of deprescribing cardiovascular medications, reasons and barriers to deprescribing, and choice of medications to deprescribe in hypothetical clinical cases.
resultsIn each specialty, 750 physicians were surveyed, with a response rate of 26% for geriatricians, 26% for general internists, and 12% for cardiologists. Over 80% of respondents within each specialty reported that they had recently considered deprescribing a cardiovascular medication. Adverse drug reactions were the most common reason for deprescribing for all specialties. Geriatricians also commonly reported deprescribing in the setting of limited life expectancy. Barriers to deprescribing were shared across specialties and included concerns about interfering with other physicians' treatment plans and patient reluctance. In hypothetical cases, over 90% of physicians in each specialty chose to deprescribe when patients experienced adverse drug reactions. Geriatricians were most likely and cardiologists were least likely to consider deprescribing cardiovascular medications in cases of limited life expectancy (all P < .001), such as recurrent metastatic cancer (84% of geriatricians, 68% of general internists, and 45% of cardiologists), Alzheimer dementia (92% of geriatricians, 81% of general internists, and 59% of cardiologists), or significant functional impairment (83% of geriatricians, 68% of general internists, and 45% of cardiologists).
conclusionsWhile barriers to deprescribing cardiovascular medications are shared across specialties, reasons for deprescribing, especially in the setting of limited life expectancy, varied. Implementing deprescribing will require improved processes for both physician-physician and physician-patient communication. J Am Geriatr Soc 68:78-86, 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.